2. Search Result
Search Result
Results for "

Gastroesophageal

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

8

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17021
    Esomeprazole

    (S)-Omeprazole; (-)-Omeprazole

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole
  • HY-114682A
    Lenperone hydrochloride

    AHR 2277

    		 Dopamine Receptor Neurological Disease
    Lenperone hydrochloride (AHR 2277) is an antipsychotic compound and a dopamine antagonist. Lenperone hydrochloride reduces gastroesophageal sphincter pressure of healthy dogs. Lenperone hydrochloride can be used for neurological disease research .
    Lenperone hydrochloride
  • HY-17021B
    Esomeprazole potassium salt

    (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole potassium salt
  • HY-17021C
    Esomeprazole hemistrontium

    (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole hemistrontium
  • HY-17021A
    Esomeprazole magnesium salt

    (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole magnesium salt
  • HY-17023
    Esomeprazole sodium

    (S)-Omeprazole sodium; (-)-Omeprazole sodium

    		 Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium
  • HY-13100
    PF 03716556

    		Proton Pump Metabolic Disease
    PF 03716556 is a potent, selective, competitive and reversible acid pump (H +,K +-ATPase) antagonist with pIC50s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H +,K +-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .
    PF 03716556
  • HY-B0160
    Lafutidine

    FRG-8813

    		 Histamine Receptor Metabolic Disease Endocrinology
    Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .
    Lafutidine
  • HY-111313
    JNJ-26070109

    		Cholecystokinin Receptor Metabolic Disease
    JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
    JNJ-26070109
  • HY-P99941
    Retifanlimab

    		PD-1/PD-L1 Cancer
    Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
    Retifanlimab
  • HY-B0656
    Rabeprazole
    2 Publications Verification

    LY307640

    		 Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole
  • HY-B0656A
    Rabeprazole sodium
    2 Publications Verification

    LY307640 sodium

    		 Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole sodium
  • HY-B0656S
    Rabeprazole-d4

    LY307640-d4

    		 Proton Pump Apoptosis Inflammation/Immunology Cancer
    Rabeprazole-d4 is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d4
  • HY-15295
    Vonoprazan Fumarate
    3 Publications Verification

    TAK-438

    		 Proton Pump Metabolic Disease
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-100007A
    Vonoprazan hydrochloride

    TAK-438 hydrochloride

    		 Proton Pump Bacterial Infection Endocrinology
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-100007
    Vonoprazan
    3 Publications Verification

    TAK-438 free base

    		 Proton Pump Bacterial Endocrinology
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-U00373
    Revexepride

    		5-HT Receptor Cytochrome P450 Neurological Disease
    Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.
    Revexepride
  • HY-19650
    Pumosetrag Hydrochloride
    1 Publications Verification

    MKC-733; DDP-733

    		 5-HT Receptor Metabolic Disease
    Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available 5-HT3 partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
    Pumosetrag Hydrochloride
  • HY-B2089
    Cinitapride

    Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .
    Cinitapride
  • HY-B0160S
    Lafutidine-d10

    		Isotope-Labeled Compounds Histamine Receptor Metabolic Disease Endocrinology
    Lafutidine-d10 is deuterium labeled Lafutidine. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease[1].
    Lafutidine-d10
  • HY-100413
    CS-526

    CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
    CS-526
  • HY-17023S
    Esomeprazole-d6 sodium

    (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium

    		 Isotope-Labeled Compounds Proton Pump Others
    Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d6 sodium
  • HY-B0732
    Itopride hydrochloride

    HSR803

    		 Cholinesterase (ChE) Dopamine Receptor Bacterial Neurological Disease
    Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .
    Itopride hydrochloride
  • HY-17021S
    Esomeprazole-d3 sodium

    		Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
    Esomeprazole-d3 sodium
  • HY-17021S1
    Esomeprazole-d3

    		Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
    Esomeprazole-d3
  • HY-B1446
    Esomeprazole magnesium

    (S)-Omeprazole magnesium; (-)-Omeprazole magnesium
    Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
    Esomeprazole magnesium
  • HY-B0732A
    Itopride

    HSR803 free base

    		 Cholinesterase (ChE) Dopamine Receptor Bacterial Others
    Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .
    Itopride
  • HY-W008614
    Lansoprazole sulfone
    1 Publications Verification

    AG-1813

    		 Proton Pump Metabolic Disease
    Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone
  • HY-17022
    Esomeprazole magnesium trihydrate

    (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate

    		 Proton Pump Endocrinology Cancer
    Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
    Esomeprazole magnesium trihydrate
  • HY-B0656AS
    Rabeprazole-d4 sodium

    LY307640-d4 sodium

    		 Isotope-Labeled Compounds Proton Pump Apoptosis Inflammation/Immunology Cancer
    Rabeprazole-d4 (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d4 sodium
  • HY-B0656AS1
    Rabeprazole-d3 sodium

    LY307640-d3 sodium

    		 Isotope-Labeled Compounds Proton Pump Apoptosis Inflammation/Immunology Cancer
    Rabeprazole-d3 (sodium)mis the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d3 sodium
  • HY-B0656AR
    Rabeprazole sodium (Standard)

    LY307640 sodium (Standard)

    		 Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole (sodium) (Standard) is the analytical standard of Rabeprazole (sodium). This product is intended for research and analytical applications. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole sodium (Standard)
  • HY-17023R
    Esomeprazole sodium (Standard)

    (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)

    		 Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium (Standard)
  • HY-W008614S
    Lansoprazole sulfone-d4

    AG-1813-d4

    		 Isotope-Labeled Compounds Proton Pump Others
    Lansoprazole sulfone-d4 (AG-1813-d4) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d4 is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone-d4 can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone-d4 has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone-d4
  • HY-10061
    Lesogaberan

    AZD-3355

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan
  • HY-10061A
    Lesogaberan napadisylate

    AZD-3355 napadisylate

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) napadisylate is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan napadisylate for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan napadisylate inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan napadisylate
  • HY-10061B
    Lesogaberan hydrochloride

    AZD-3355 hydrochloride

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) hydrochloride is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptor. The affinity (Kis) of Lesogaberan hydrochloride for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan hydrochloride inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan hydrochloride
  • HY-B0310
    Nizatidine

    		Histamine Receptor Inflammation/Immunology Endocrinology Cancer
    Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .
    Nizatidine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: